[EN] IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS<br/>[FR] COMPOSÉS D'IMIDAZOTÉTRAZINE ET TRAITEMENT DE CANCERS RÉSISTANTS AU TMZ
申请人:[en]THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
公开号:WO2023150569A1
公开(公告)日:2023-08-10
Imidazotetrazines were designed to evade resistance byO6-methylguanine DNA methyltransferase (MGMT) while retaining suitable hydrolytic stability, allowing for effective prodrug activation and biodistribution. One compound, called TABZ, exhibits activity against cancer cells irrespective of MGMT expression and MMR status. TABZ has comparable blood-brain barrier penetrance and comparable hematological toxicity relative to TMZ, while also matching its maximum tolerated dose (MTD) in mice when dosed once-per-day over five days. The activity of TABZ is independent of the two principal mechanisms suppressing the effectiveness of TMZ, making it a promising new candidate for the treatment of GBM, especially those that are TMZ resistant.
Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent
作者:Malcolm F. G. Stevens、John A. Hickman、Robert Stone、Neil W. Gibson、Ghouse Unissa Baig、Edward Lunt、Christopher G. Newton
DOI:10.1021/jm00368a016
日期:1984.2
Interaction of 5-diazoimidazole-4-carboxamide and alkyl and aryl isocyanates in the dark affords 8-carbamoyl-3-substituted-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-on es. In cold methanol or ethanol, the 3-(2-chloroethyl) derivative 7a decomposes to afford 2-azahypoxanthine (14) and methyl and ethylN-(2-chloroethyl)carbamates, respectively. Compound 7a has curative activity against L-1210 and P388 leukemia